Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    Review

    de Castria, T. B.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Tractable patient-derived models for preclinical therapeutic studies of CNS metastases
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
    Meeting Abstract

    Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
    Meeting Abstract

    Thouvenin, J.; Alhalabi, O.; Carlo, M.; Ajuria, L. C.; Bakouny, Z.; Chanza, N. M.; Negrier, S.; Campedel, L.; Bilen, M. A.; Borchiellini, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Meeting Abstract

    Keane, F.; Park, W.; Varghese, A.; Balogun, F.; Yu, K.; El Dika, I.; Khalil, D.; Kelsen, D. P.; Reidy-Lagunes, D.; Ku, G. Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Chesney, J.; Wise-Draper, T.; Sarnaik, A. A.; Finckenstein, F. G.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Warner, A. B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
    Meeting Abstract

    Migden, M. R.; Schmults, C.; Khushanlani, N.; Guminski, A.; Chang, A. L.; Lewis, K.; Ansstas, G.; Bowyer, S. E.; Hughes, B. G. M.; Schadendorf, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save